Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Junzhang Zhao"'
Autor:
Junjie Yan, Yingying Zeng, Zerong Guan, Zhenhua Li, Shunchang Luo, Jie Niu, Junzhang Zhao, Haibiao Gong, Ting Huang, Zhongzhen Li, Anyi Deng, Qiong Wen, Jingyi Tan, Jun Jiang, Xiucong Bao, Sitao Li, Guodong Sun, Min Zhang, Min Zhi, Zhinan Yin, Wan-Yang Sun, Yi-Fang Li, Rong-Rong He, Guangchao Cao
Publikováno v:
Cell Reports, Vol 43, Iss 8, Pp 114636- (2024)
Summary: Inflammatory bowel disease (IBD) has high prevalence in Western counties. The high fat content in Western diets is one of the leading causes for this prevalence; however, the underlying mechanisms have not been fully defined. Here, we find t
Externí odkaz:
https://doaj.org/article/4904def4f06644938614f25995a7af42
Autor:
Jiayin Yao, Xiang Peng, Yingkui Zhong, Tao Su, Adam Bihi, Junzhang Zhao, Tao Liu, Wei Wang, Pinjin Hu, Min Zhang, Min Zhi
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
ObjectivesUstekinumab (UST) optimization strategies, including shortening intervals and intravenous reinduction, should be administered to patients with partial or loss of respond. Evidence comparing these types of optimization treatments is limited.
Externí odkaz:
https://doaj.org/article/65d92378ac7b4a9fb26466874f9e3929
Autor:
Wenguang Peng, Jiarui Yang, Long Xia, Xiangjun Qian, Guojie Long, Hao Zhang, Jiancong Xie, Junzhang Zhao, Lei Zhang, Weidong Pan
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionImmunogenic cell death (ICD) is a sort of regulated cell death (RCD) sufficient to trigger an adaptive immunological response. According to the current findings, ICD has the capacity to alter the tumor immune microenvironment by generatin
Externí odkaz:
https://doaj.org/article/e16ce996dcf24e719a144f478cd6e33d
Autor:
Xiaoling Hong, Kai Zhuang, Na Xu, Jiang Wang, Yong Liu, Siqi Tang, Junzhang Zhao, Zunnan Huang
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2023)
The pathogenesis and vital factors of early and progressive stages of stomach adenocarcinoma (STAD) have not been fully elucidated. In order to discover novel and potential targets to guide effective treatment strategies, a comprehensive bioinformati
Externí odkaz:
https://doaj.org/article/bc0fbac7234846eb815d3e33c54df074
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66976 (2013)
Previous genome-wide association studies (GWAS) in multiple populations identified several genetic loci for coronary heart diseases (CHD). Here we utilized a 2-stage candidate gene association strategy in Chinese Han population to shed light on the p
Externí odkaz:
https://doaj.org/article/2b81b29d66064b8792dace1e5d9fd1b4
Autor:
Murthy, Divya, Attria, Kuldeep S., Suresh, Voddu, Rajacharya, Girish H., Valenzuela, Carlos A., Thakur, Ravi, Junzhang Zhao, Shukla, Surendra K., Chaika, Nina V., LaBreck, Drew, Rao, Chinthalapally V., Hollingsworth, Michael A., Mehla, Kamiya, Singh, Pankaj K.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America; 4/2/2024, Vol. 121 Issue 14, p1-12, 25p
Autor:
Jiayin Yao, Jie Zhou, Yingkui Zhong, Min Zhang, Xiang Peng, Junzhang Zhao, Tao Liu, Wei Wang, Pinjin Hu, Xiaochun Meng, Min Zhi
Publikováno v:
Medical Physics.
Publikováno v:
Clinical Gastroenterology.
Autor:
Min Zhi, Jiayin Yao, Heng Zhang, Bang Hu, Xiang Peng, Junzhang Zhao, Tao Liu, Wei Wang, Pinjin Hu, Min Zhang
Aim: Data of Ustekinumab (UST) in treating perianal fistulizing Crohn’s disease (CD) are limited in China. We aimed to evaluate the efficacy of UST in the real-world setting. Methods: We retrospectively analyzed patients with perianal fistulizing C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99e2bf920a04cf7881d3633167a4e901
https://doi.org/10.21203/rs.3.rs-1354312/v1
https://doi.org/10.21203/rs.3.rs-1354312/v1
Autor:
Jiayin Yao, Heng Zhang, Tao Su, Xiang Peng, Junzhang Zhao, Tao Liu, Wei Wang, Pinjin Hu, Min Zhi, Min Zhang
Publikováno v:
Journal of Clinical Medicine
Volume 12
Issue 3
Pages: 939
Volume 12
Issue 3
Pages: 939
There is insufficient evidence to confirm the efficacy of ustekinumab (UST) in promoting fistula closure in perianal fistulizing Crohn’s disease (CD) patients. We aimed to evaluate the efficacy of UST in a real-world setting. The data were retrospe